Michael Philip Dybbs
Independent DirectorDr. Michael Philip Dybbs, also known as Mike, Ph.D., serves as Director at Claris Biotherapeutics, Inc. since July 2026. He serves as an Independent Director at SpyGlass Pharma, Inc. since November 2025. He is a Director at Kalaris Therapeutics, Inc. since March 2022 and also its Co-Founder. He is Board Director of Abcuro, Inc. He serves as Director of Levo Therapeutics, Inc. He serves as Investor & Director at Fluent BioSciences Inc. He serves as Director at IonPath, Inc. He serves as the Director at Delfi Diagnostics, Inc. He is an Independent Director of Sutro Biopharma, Inc. since July 25, 2018. He had been a Director at Enara Bio Limited until 2024. He served as a Director of RayzeBio, Inc. until 2022. Dr. Dybbs is a Partner of Samsara BioCapital since March 2017. He serves as a Director of Nkarta Therapeutics. He also serves as Founding Partner of Dimension Therapeutics. Dr. Dybbs served as a Partner at New Leaf Venture Partners since May 2009 until September 2016. Dr. Dybbs was a Principal at New Leaf Venture Partners, L. L.C. since 2012. He joined New Leaf Venture Partners in 2009 as an Associate. Dr. Dybbs was a Principal at The Boston Consulting Group, where he was a core Member of their Health Care practice. At the firm, he led projects in the biopharmaceutical industry across a range of functions and therapeutic areas. Dr. Dybbs worked as an independent Biotechnology Consultant, performing such projects as identifying assets at both universities and medical centers, as well as evaluating spin-outs of discovery stage research programs. The research had been published in peer-reviewed journals, including Neuron, Science and Nature. Dr. Dybbs serves as Independent Director at Nkarta, Inc. since August 2019. He had been a Director of Advanced Cell Diagnostics, Inc., since April 2015. He served as a Director of Principia Biopharma Inc. and served as its Board Observer. He served as an Independent Director of Dimension Therapeutics, Inc. since April 21, 2015 until November 7, 2017. Dr. Dybbs served as a Director at Versartis, Inc. from March 2013 to July 21, 2014. He serves as a Director of Respira Therapeutics. He holds a Ph. D. in Molecular and Cellular Biology and Genetics from University of California, Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship; and received an A. B. in biochemical sciences from Harvard College.
Positions
- Company NameNkarta, Inc.Stock CodeNKTXPositionIndependent Director
- Company NameKalaris Therapeutics, Inc.Stock CodeKLRSPositionCo-Founder & Director
